Filing Flows › Protalix BioTherapeutics (PLX) › Stock forecast & fair value
Protalix BioTherapeutics (PLX) stock forecast and price target
Protalix BioTherapeutics (PLX) trades at $2.54. 2 analysts' median price target is $11.00 (+333%), from $10.00 to $12.00.
Protalix BioTherapeutics' latest quarter
Protalix BioTherapeutics, Q2 2026: revenue $19.9M (+27% year over year), operating margin 23.5%, net earnings $3.8M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for PLX stock?
The median of 2 analysts' 12-month targets is $11.00, +333% from $2.54; the range is $10.00 to $12.00. The average rating is none.
Does Protalix BioTherapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is PLX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.